Key words: arginine vasopressin (AVP), pro-arginine vasopressin (proAVP), vasopressin-associated glycopeptide (VAG), monoclonal antibody (mAb), extracellular signal-regulated kinase (ERK), neurophysin-related surface antigen (NRSA)
Introduction
The neuropeptide arginine vasopressin (AVP) is generated in and secreted by hypothalamic neurons. The preprovasopressin precursor protein is $17 kDa, and after an N-glycosidic side-chain of $4 kDa is added, the resulting $20 kDa provasopressin (proAVP) product is packaged into secretory vesicles. It undergoes enzymatic modification to generate AVP, vasopressin-associated neurophysin (VP-NP), and vasopressin-associated glycopeptide (VAG) [1] . Three G-protein coupled receptors (V1a, V1b, and V2) mediate the biological influence of AVP [2, 3] . Additionally, the vasopressin-activated calcium mobilizing (VACM) protein has been described as a putative AVP receptor, although very little is known about its role in cell function [4] . Generally, signaling through the V1 receptors can involve the activation of phospholipase A2, C, D, and protein kinase C, leading to an increase in intracellular free Ca 2+ , and the activation of the mitogen-activated protein kinase (MAPK) and focal adhesion kinase (FAK). Signaling through the V2 receptor involves the activation of adenylate cyclase, protein kinase A, and a rise in intracellular cAMP. AVP aids in the regulation of blood pressure through the V1a receptor pathway, in the regulation of the adrenal-stress axis through the V1b receptor pathway, and acts as an antidiuretic through the V2 receptor pathway [2] . The biological functions of AVP are well defined, but those of VP-NP and VAG are not as well characterized. It is clear the VP-NP is important in the proper intracellular transport and processing of proAVP [5] [6] [7] . There are eight disulfide bridges within the 93 amino acids of the human VP-NP structure of proAVP, and further structural complexity is added through oligomerization. The processing of proAVP is dependent not only on protein sequence, but also on this oligomerization [5] [6] [7] . Although VAG is conserved among most mammals, its precise function remains elusive. One study indicates that it is important for the proper folding of proAVP [8] , however another study suggests that it is not essential for proper proAVP processing [9] . The AVP gene is expressed in neuroendocrine tumors, while there is a low incidence of expression in the non-neuroendocrine tumor types examined [10] . AVP receptor signaling can initiate both mitogenic and anti-proliferative effects on tumors and cultured tumor cells [11] [12] [13] [14] [15] . It has been suggested that the mitogenic effects of AVP are mediated through the V1 receptor, while the anti-proliferative effects are mediated through the V2 receptor [16] [17] [18] [19] . The majority of research on AVP production and signaling in cancer has focused on small cell lung cancer (SCLC), such as the impact of glucocorticoids on AVP expression [20, 21] , promoter elements and transcription factors involved in AVP expression [22] [23] [24] [25] [26] [27] , detection of proAVP protein forms expressed [28, 29] , immunohistochemical screening of human tissues for proAVP protein products [10, 30, 31] , and intracellular mechanisms of AVP-stimulated proliferation [19] . Few such studies have been performed on other cancers that express neuropeptides, such as breast cancer. Breast cancer cells express all known AVP receptors [16] , which can mediate AVP-induced growth in these cells [11] . In separate studies, we demonstrated that AVP appears to be expressed by all breast cancers, but not by the majority of normal tissues [30, 31] . The current study shows that the proAVP message is present in all of the 5 cultured cell lines examined. Western analysis of cultured breast cancer cell lysates revealed multiple forms of proAVP protein, similar to what has been reported in cultured SCLC cells. Additionally, antibodies directed against the VP-NP or the VAG region of proAVP protein bind to live intact Mcf7 and Skbr3 cells. These cells are also able to secrete VAG, and in the case of the Skbr3 cells, VAG levels are increased in response to treatment with a cocktail of dexamethasone, 3-isobutyl-1-methylxanthine, and 8-bromoadenosine 3¢,5¢-cyclic monophosphate. Exogenous AVP can act to promote growth though the V1 receptors by a process that appears to involve MAPK (ERK1/2) activation. Alternatively, activation of the V2 receptor in Mcf7 and Skbr3 cells by the specific agonist dDAVP resulted in a slight decrease in proliferation.
Methods

Cell culture and human tissue
Cultured cell lines were maintained at 37°C and 5% CO 2 . The breast cell lines were obtained from the ATCC (Rockville, MD) and cultured in DMEM-F12 (Mediatech, Herndon, PA) with 10% FBS (Hyclone, Logan, UT). The Lu-165 classical-type SCLC cell line, developed by Dr. T. Terasaki (Tokyo, Japan, [32] 
Anti-proAVP antibodies
Antibody production and characterization have been described previously for the monoclonal antibody (mAb) against the VAG region, MAG1 [28] , the mAb against the VP-NP region, NAB1 [10] , and the polyclonal antibody against the VAG region [31] .
RT-PCR
Reactions were performed using an Eppendorf Mastercycler Gradient thermocycler (Brinkmann, Westbury, NY). Total RNA was isolated from cultured cells or human tissues using TRIzol (Gibco BRL, Rockville, MD), and 1 lg was used together with oligo-dT primers and RNase H ) reverse transcriptase (Invitrogen, Carlsbad, CA) following the manufacture's instructions. PCR amplification was performed using Eppendorf DNA Taq polymerase in a standard 30-cycle reaction. The proAVP message was amplified using the following primers, which are designed to amplify the entire coding sequence, and an annealing temperature of 56.4°C.
Forward: cttctcctccgcgtgcta Reverse: cgtccagctgcgtggcgttgct ReadyMade Primers (Integrated DNA Technologies, Skokie, IL) specific for Gapdh were used for control reactions, carried out using an annealing temperature of 54°C. RT-PCR products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining and an Alpha Innotech FluorChem 8900 (San Leandro, CA).
AVP-induced ERK1/2 activation and cell proliferation
Skbr3 and Mcf7 cells were seeded onto plastic culture dishes or multi-well plates and allowed to adhere overnight. For assessment of ERK1/2 activation, the cells were serum-starved in RPMI without phenol red containing 1% BSA and for 12 h prior to treatment with AVP. Cells were lysed (HEPES 20 mM, NaCl 150 mM, glycerol 10%, Triton X-100 0.5%, DTT 1 mM, Na 3 VO 4 1 mM, b-glycerophosphate 25 mM, NaF 1 mM, Completeä 1 tablet/50 ml) and subjected to Western analysis as described below. For assessment of cell proliferation, cells were cultured overnight in RPMI containing 5% charcoal-stripped FCS prior to treatment. The media was then replaced with identical media containing 10% alamarBlue (BioSource, Camarillo, CA). Dilutions of untreated cells were prepared and incubated in alamarBlue concurrently to generate a standard curve and ensure readings were measured in a linear range. Duration of treatments and concentrations of AVP, the AVP derivative and specific V2 agonist desmopressin (dDAVP), the V1a receptor antagonist SR49059, and the V2 receptor antagonist SR121463, are indicated in the text and figure legends. The receptor antagonists were a kind gift from Dr. C. Serradeil-Le Gal (Sanofi Recherche, France).
ELISA and RIA for proAVP
Approximately 10 4 cells were seeded onto 12-well plates, cultured overnight, and then kept in serum-free conditions for 18 h prior to treatment. After which, they were treated with dexamethasone or a cocktail of dexamethasone, 3-Isobutyl-1-methylxanthine (IBMX), and 8-bromoadenosine 3¢,5¢-cyclic monophosphate (8br-cAMP). The final concentrations of treatment reagents were: 50 nM dexamethasone, 0.5 mM IBMX, and 0.5 mM 8br-cAMP. Treatment was carried out over 4 days with the media and treatment reagents changed on the second day. The media was then removed and replaced with PBS. After 1 h at 37°C, the PBS was removed and used for RIA. Cells were lysed in TBS with 0.1% Tween-20 containing a cocktail of protease inhibitors (Roche). Protein concentrations were determined by BCA (Pierce), which indicated that total protein yields were similar regardless of treatment. A synthetic peptide representing the C-terminal 18 amino acids of the human VAG region (VAGc18) was conjugated to BSA using gluteraldehyde, and used to coat the wells of Microfluor 2 Black ELISA plates (Dynex Technologies, Chantilly VA). Additionally, some wells were coated with glutaraldehyde-treated BSA to serve as a non-specific binding control. Plates were incubated in blocking buffer (TBS, 0.1% BSA, 0.05% Tween-20, 0.01% NaN 3 , pH 7.2) for 30 min at room temperature. Lysate (50 lg) was reacted with MAG1 (2 ng) or nonspecific isotype control mAb (ICN Pharmaceuticals) in 100 ll of PBS in the microtiter plate wells for 2 h at 37°C. Plates were then incubated with biotinylated goat anti-mouse (Fab-specific, Sigma) for 1 h, and alkaline phosphatase-conjugated streptavidin (Calbiochem) for 1 h. Washes were performed in between each successive incubation using blocking buffer. A final wash was performed using substrate buffer (0.05 M Na 2 CO 3 , 0.05 mM MgCl 2 ), after which fluorogenic substrate (0.2 mM 4-methylumbelliferyl phosphate) in substrate buffer was added to the wells and readings were taken using 365 nm excitation and 450 nm emission wavelengths on a Synergy HT plate reader (Bio-Tek Instruments). A standard curve was generated using dilutions of unconjugated VAGc18 incubated with 2 ng MAG1. RIA was performed to detect products secreted into the PBS media as described earlier for AVP [33] using the polyclonal antibody against the VAG region and 125 I-labeled VAGc18.
Immunofluorescence and cytometric analysis
Binding of anti-proAVP mAbs to live intact cells was assessed by indirect immunofluorescent analysis. Cells were seeded onto glass coverslips and cultured overnight. Iced-cold PBS containing 0.1% BSA and 0.01% NaN 3 was used for washes and antibody incubations. Cells were washed and incubated at room temperature for 1 h in buffer containing 40 lg/ml anti-proAVP mAbs or isotype-matched antibodies IgG1 (MopC21, MP Biomedicals, Aurora OH) and UPC-10 (IgG2a, Sigma, St. Louis MO) as controls for MAG1 and NAB1, respectively. After four washes, the cells were fixed using 0.5% paraformaldehyde in PBS for 20 min rinsed four times with PBS, and incubated at room temperature for 1 h in buffer containing a 1:50 dilution of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (ICN). Coverslips were mounted utilizing SlowFade Light (Molecular Probes, Eugene, OR), and fluorescence was recorded using a Micropublisher camera (Qimaging, Burnaby, British Columbia, Canada) connected to a BX51 microscope (Olympus, Melville, NY) with UPlanAPO and UPlanFL optics. Flow cytometry was performed on cells that had been removed from their culture flasks using CellStripper cell dissociation solution (Mediatech) and reacted with antibody as described above and the fluorescence was measured on a FACStar flow cytometer (Becton Dickinson, Mountain View CA).
Western analysis
Cultured cell protein samples were separated on 12.5% gels by SDS-PAGE (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3), and then transferred onto Immobilon-P PVDF membrane (Millipore, Bedford, MA) in the Tris-glycine buffer with 20% methanol added, using the MiniProtean 3 system (BioRad, Hercules, CA). Membranes were blocked using 5% non-fat dried milk in Tris-buffered saline with 0.1% Tween-20 (TBST), and proAVP was detected using the antibody indicated in the text at a dilution of 1 lg/ml for the mAbs. After washing, a goat anti-mouse HRP-conjugated secondary antibody was employed (Santa Cruz Biotechnology, Santa Cruz CA) and detection was carried out using chemiluminescent substrate (Pierce, Rockford IL), and exposure to autoradiography film. If membranes were to be re-probed, antibodies were stripped from the membranes by incubation in 0.1N NaOH for 5 min at room temperature, washed in TBST, blocked, and subjected to incubation with a different primary antibody. Mouse monoclonal anti-Gapdh antibody (Chemicon International, Temecula CA) was used as an assay control. For the detection of phospho-ERK1/2, blots were blocked in PBS containing 0.5% Tween-20, and then incubated in the same buffer containing a 1 lg/ml dilution of antiphospho-p42/44 MAPK polyclonal antibody (Cell Signaling Technology, Beverly MA). The remainder of the procedure was that as described above using a goat antirabbit HRP-conjugated secondary antibody (ICN), and after stripping the membranes they were re-probed using anti-p42/44 MAPK (Cell Signaling Technology). [34] .
Results
Expression
Detection of proAVP protein forms by Western analysis
Skbr3 and Mcf7 whole cell lysates, and extracts of human hypothalamic tissue were subjected to Western analysis utilizing MAG1 and NAB1 anti-proAVP mAbs. In both cell lines, a doublet at 38/41 kDa and a band at 20 kDa were detected using the proAVP antibodies ( Figure 2 ). These results are similar to what we observed in SCLC cell lines and tissue extracts with MAG1 and in breast cancer tissue with NAB1 [28, 31] . MAG1 also detected prominent bands at 38 kDa and at 20 kDa in human hypothalamic paraventricular nucleus (PVN) and supraoptic nucleus (SON) tissue extract, while NAB1 detected a single band at 38 kDa. The nature of these proAVP forms is not entirely known, however studies suggest that proAVP multimers exists as a product of VP-NP region-dependant interactions that may be resistant to reduction [5, 6, 35] . It does appear that some antibodies generated against proAVP are not able to readily react with all of the individual molecular mass forms that have been identified [35] .
Immunofluorescent analysis using proAVP mAbs
We have demonstrated that epitopes of proAVP are accessible to antibodies in live intact SCLC cells [21, 28, 29, 36, 37] . Similarly, proAVP was detected in live intact Skbr3 and Mcf7 cells by immunofluorescent analysis, utilizing mAbs against the VAG or VP-NP region (MAG1 or NAB1, respectively). Detection at the surface region of these cells (Figure 3a , c, f) indicates the availability of the neurophysin-related surface antigen (NRSA) [28, 29] . No reaction was observed with isotype control antibodies. Skbr3 cells are know to have a high level of ErbB2 at their surface, and the localization of . Direct sequence analysis of the Mcf7 and Skbr3 PCR product using nested primers indicated normal proAVP message. Products were separated on a 1.5% agarose gel, which was then stained with ethidium bromide. Only one band was detected and that correlated to the predicted size (365 bp) for the amplification product. Direct sequence analysis using nested primers indicates normal provasopressin message.
staining observed using MAG1 and NAB1 appeared similar to that observed on Skbr3 cells using an antiErbB2 mAb (Figure 3e ). To contrast the surface region localization, cells were fixed and permeabilized with methanol prior to reaction with anti-proAVP mAbs, revealing diffuse cytoplamic staining (Figure 3b, d ).
proAVP VAG levels and secretion by Mcf7 and Skbr3 cells
Glucocorticoids and cAMP-dependant signaling pathways can regulate AVP gene expression. Previous studies demonstrated that dexamethasone decreased the proAVP mRNA and VP-NP protein expression in SCLC cells, while a cocktail containing dexamethasone, IBMX and 8br-cAMP increased their expression [20, 21] .
Mcf7 and Skbr3 cells were subjected to similar treatments to examine the effect on intracellular and secreted proAVP levels. Cells were cultured in the presence of dexamethasone or a combination of dexamethasone, IBMX, and 8br-cAMP for 4 days. The cells were briefly washed and then incubated in PBS for 1 h. The PBS was collected to measure secreted VAG by RIA, and the cells were lysed to measure cellular VAG by ELISA. Secreted VAG levels in the control samples were found to be similar in the Skbr3 and Mcf7 cells (Figure 4a ). Dexamethasone treatment increased the amount of VAG secreted by the Skbr3 cells, but had no effect on the Mcf7 cells. The amount of secreted VAG detected in the media was not altered after treatment with the dexamethasone, IBMX, and 8br-cAMP cocktail over the course of the assay. Cellular VAG levels in control samples were also found to be similar in both cell lines (Figure 4b ), and they remained unchanged after dexamethasone treatment. The amount of VAG detected in 
AVP-induced ERK1/2 activation and cell proliferation
Recently, we demonstrated that AVP activated ERK1/2 in SCLC cells and increased their proliferation [19] . (Figure 7a ). AVP at 1 nM increased cell proliferation about 10%, and AVP at 100 nM increased cell proliferation about 20% (not shown). The differences in proliferation observed between 10 nM and 100 nM were not statistically significant, therefore a concentration of 10 nM was chosen for subsequent experiments. AVP (10 nM) increased Mcf7 and Skbr3 cell proliferation by approximately 8% and 15% at day 1, and by approximately 22% and 19% at day 3, respectively. The increase observed at day 3 is comparable to what we observed for H345 and H146 SCLC cells [19] . We have shown that AVP-induced SCLC cell proliferation is mediated by the V1a receptor [19] . Therefore, the V1a receptor antagonist SR49059 was used to examine the impact of endogenous and exogenous AVP on breast cancer cell proliferation. When Mcf7 cells were incubated with both SR49059 (10 nM) Figure 2 . proAVP forms are present in breast cancer cell lysates and human hypothalamic tissue extracts. Lysates and extracts were analyzed by SDS-PAGE using a 12.5% gel and Western blot using MAG1 and NAB1 mAbs. Since proAVP is normally expressed by the hypothalamus, extracts from regions of the human hypothalamus (PVN: paraventricular nucleus, SON: supraoptic nucleus) were used for comparison with the breast cell lysates. Molecular mass markers (kDa) are indicated on the left side of the figure. and AVP (10 nM), the AVP-induced increase in proliferation at day 3 was reduced from 22% to 15% that of the untreated cells. When Skbr3 cells were incubated with both SR49059 and AVP, their proliferation was similar to untreated cells. Thus, it appeared the SR49059 reduced the exogenous AVP-induced growth in Mcf7 cells and abolished it in Skbr3 cells. When Mcf7 and Skbr3 cells were cultured in the presence of 10 nM SR49059 alone, they displayed similar growth as untreated control cells (not shown). The V2 agonist dDAVP appears to inhibit breast cancer cell metastasis [18, 38] , and the V2 receptor may mediate anti-proliferative effects [17] . Cells were exposed to 10 nM dDAVP alone or in the presence of the V2 antagonist SR121463 and their proliferation was measured. dDAVP (10 nM), reduced proliferation in Mcf7 and Skbr3 cells to 92% and 93% that of controls at day 3, respectively ( Figure 7b ). Although the decrease in proliferation was not dramatic, it could be blocked by co-incubation with the selective V2R antagonist SR121463 in both cell lines, indicating the anti-mitogenic effect of dDAVP results from V2 receptor activation. As expected, SR121463 alone had no effect on the proliferation of either cell line (not shown). 
Discussion
Little is known about the regulation of proAVP or AVP-mediated signaling in breast cancer, and the present study was designed to address some basic issues in this regard. We have demonstrated that proAVP mRNA is present in all 5 of the cultured cell lines examined, regardless of their reported levels of ERa expression, ErbB2 expression, p53 status, or tumor origin. Interestingly, we found proAVP mRNA in Mcf10a cells, Figure 4 . Dexamethasone (Dex) or a combination of dexamethasone, IBMX, and 8br-cAMP can regulate proAVP production and secretion in Skbr3 cells. (a) RIA was performed to measure secreted VAG using a polyclonal antibody directed against the VAG region of proAVP and iodinated-VAGc18 peptide, and the amount of bound iodinated-VAGc18 peptide was compared to a standard curve. (b) ELISA was carried out to determine VAG concentration in cell lysates using 96-well plates coated with VAGc18 peptide conjugated to BSA. MAG1 (1 lg/ml) was reacted with cell lysate (50 lg) in the coated wells, or with dilutions of VAGc18 to generate standard curves. Biotinylated goat anti-mouse and alkaline phosphatase-conjugated streptavidin were used to detect MAG1 bound in the wells. Fluorogenic substrate (0.2 mM 4-methylumbelliferyl phosphate) was used to generate signal and the relative fluorescence from each sample was compared to a standard curve to determine the concentration of VAG in those samples. The values plotted represent the mean obtained in each treatment group (± SEM). Dark gray: Mcf7, Light gray, Skbr3. * t-test p £ 0.05 compared to controls.
which are derived from a spontaneously immortalized outgrowth of fibrocystic disease breast cells [39] . Immunohistochemical studies performed by us indicate that fibrocystic tissue specimens, not associated with malignant disease, do not contain proAVP protein products [30] . Although Mcf10A cells have been employed as cells from a non-cancerous origin, their expression profile of nuclear matrix proteins appears to be comparable to breast tissue that is between a normal and cancerous state [40] . It is possible then, that the expression of genes encoding neuropeptides and their receptors is a process associated with cellular immortalization. Recently, it was demonstrated that expression of the human V1a receptor in CHO cells resulted in a transformed phenotype that was associated with a loss of contact inhibited growth [41] . In apparent agreement with this notion, it was shown that activation of PI3K is essential for the transformation of human mammary epithelial cells in culture [42] . Western analysis with a mAb directed against the VAG region (MAG1) or the VP-NP region (NAB1) of proAVP revealed the presence of multiple proAVP forms in Mcf7 and Skbr3 cells. These results are similar to earlier reports that demonstrated proAVP forms of approximately 40, 30, and 20 kDa in SCLC cell lines and tumor extracts [28, 29, 31] . Mcf7 and Skbr3 cells express a proAVP message that contains a normal sequence, therefore these forms should not be due to an abnormal prohormone. Additionally, we show that . ERK1/2 is activated in breast cancer cells in response to exogenous AVP. Cells were cultured overnight in media containing 5% charcoal-stripped FCS prior to AVP treatment. They were incubated continuously for 5 or 15 min in 1, 10, or 100 nM AVP at 37°C. Total cell lysates were prepared and subjected to Western analysis using antiphospho-p42/44 MAPK (P-ERK) and anti-p42/44 MAPK (ERK) antibodies. This assay was repeated twice using the Skbr3 cell line and three times using the Mcf7 cell line with similar results. some of these forms are present in human hypothalamic extracts, although the 42 kDa appears to be less prominent than in the tumor cell extracts. Other reports have identified higher molecular mass VP-NP-related species in extracts of bovine pituitary [35, 43] , rat and mouse hypothalamus [44] [45] [46] [47] , and human posterior pituitary [48] . The exact nature of the these forms has not been precisely determined, but the proAVP protein signal peptide is known to have an unusual sequence, which makes the processing of the protein inefficient and allows for its missorting even under normal circumstances [49] . Moreover, proAVP oligomerization may be an integral part of its processing and trafficking [5] [6] [7] , and higher molecular mass forms of proAVP have been found to be resistant to reduction by various agents [35, 43, [45] [46] [47] . These forms and their stability may be a result of the 8 disulfide bridges within the 93 amino acids that comprise the VP-NP region of proAVP, and further structural complexity may be added as a result of oligomerization. This in turn may yield forms of pro-AVP that are not readily recognized by some antibodies that have been generated against certain regions of the proAVP sequence [35] . Hence, the slight difference in the proAVP forms detected using the MAG1 or the NAB1 mAbs in Western analysis is likely due to epitope availability. Anti-proAVP antibodies are able to bind to the surface region of SCLC cells [21, 28, 29, 36, 37] , and here we show that this appears to hold true for breast cancer cells as well. Indeed, MAG1 and NAB1 mAbs displayed a pattern of immunoreactivity on live cells that was similar to that observed using an anti-ErbB2 mAb, and distinctly different from the diffuse staining observed in permeabilized cells. We have postulated that these epitopes are provided by unprocessed proAVP, and comprise what we have termed the neurophysinrelated surface antigen (NRSA) [28, 29] .
We are particularly interested in the use of the MAG1 mAb for detection of NRSA, in part because endogenously produced VAG has not been ascribed a biological function. External stimuli such as glucocorticoids are known to affect AVP gene transcription, and can regulate the amount of immunodetectable proAVP in SCLC cells [21] . Cellular and secreted VAG produced by Mcf7 and Skbr3 cells was measured, as was their response to dexamethasone or a combination of dexamethasone, IBMX, and 8br-cAMP. Dexamethasone alone did not produce a measurable change in cellular VAG levels in either cell line, but it appeared to increase the amount secreted from Skbr3 cells. It is conceivable that the actions of dexamethasone on AVP gene transcription were not apparent because of the timeframe we considered. Additionally, factors such as differing levels of glucocorticoid receptor expression between the two cell lines may account for the selective effect of the steroid on AVP secretion from the Skbr3 cell line. We might have expected that the cocktail of dexamethasone, IBMX, and 8br-cAMP would increase the proAVP levels in Skbr3 cells and its secretion from them, but we found only the cellular levels to be increased. It would appear that the proAVP production and secretion pathways are not precisely coordinated in Skbr3 cells to effectively process and release AVP. The cocktail had no apparent effect on Mcf7 cells. The notion that alterations in the protein kinase A and C pathways are early and later events in breast cancer malignant transformation, respectively [50] may at least in part account for these differences. Rates of protein production, processing, or secretion were not determined, therefore these data do not indicate by which particular process such differences are manifested. However, dexamethasone has been shown to decrease, while the combination of dexamethasone, IBMX, and 8br-cAMP has been shown to increase the expression of AVP mRNA as well as AVP and VP-NP protein levels in cultured SCLC cells [20, 21] . Additionally, 8br-cAMP was shown to increase the amount of AVP released from rat posterior pituitary explants, but it had no effect on AVP mRNA content in the supraoptic nucleus [51] . A recent report indicates that proAVP protein levels are unchanged in human hypothalamus tissue sections from patients who received dexamethasone treatment, compared to those who did not, but the levels of mature AVP are decreased [52] . This effect could not be explained entirely by the downregulation of processing enzymes. Thus, it appears that the regulation of AVP expression can be a very complex and cell-specific process [53] . These measurements were undertaken to determine if breast cancer cells display some of the regulatory aspects observed with SCLC cells with respect to proAVP expression. Although VAG was found to be secreted by the Mcf7 and Skbr3 cells, it was clear that there was cell-associated VAG that could be bound by MAG1. In the case of Skbr3 cells, treatment with a combination of dexamethasone, IBMX, and 8br-cAMP enhanced their immunoreactivity with MAG1 mAb. These results are in agreement with earlier findings with H69 SCLC cells, and supported the notion that by inducing an increase in production of proAVP by tumor cells, immuno-based detection and treatment efforts may be enhanced [31] .
It is believed that neuropeptides and their receptors can form an autocrine/paracine growth loop in certain tumor cells. There are cases in the literature that describe the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in breast cancer patients [54] [55] [56] , indicating that at least some breast cancer cells are capable of producing and secreting biologically active AVP. Mcf7 cells express the V1a, V1b and V2 AVP receptors [16] , as well as the key enzymes required for the processing of the proAVP peptide [57] . We did find that the VAG region of proAVP was secreted by Mcf7 and Skbr3 cells, although we did not assess whether biologically active AVP was produced. However, exogenous AVP was found to activate ERK1/2 and increase the proliferation of these cells, which was comparable to what we observed with SCLC cells [19] . Activation of the V1a receptor has been shown to increase the levels of phosphorylated ERK1/2 and mediate the AVP-induced proliferation of SCLC cells, intestinal epithelial cells, and in V1a receptor-transfected cells [19, [58] [59] [60] . Our results suggest that a similar growth promoting mechanism occurs in breast cancer cells in response to AVP. The transient AVP-induced ERK1/2 phosphorylation detected in the Skbr3 cell line is in agreement with data obtained on SCLC cells [19] , but the ERK1/2 activation persisted longer in the Mcf7 cells. A recent report demonstrates a difference in the level and duration of ERK1/2 phosphorylation in Mcf7 cells in response to estradiol or IGF-1 [61] . Another study showed that ErbB2 overexpression in Mcf7 cells reduced IGF-1-induced ERK phosphorylation, and IGF-1-induced ERK phosphorylation was restored in Skbr3 cells overexpressing the IGF-1 receptor during antisensemediated ErbB2 downregulation [62] . Additionally, estrogen-induced ERK1/2 activation in Mcf7 cells was shown to be dependant on the membrane ERa levels [63] . Thus, while the precise mechanisms responsible for the variation we observed between the two cell lines remain to be defined, the expression levels of membrane receptors, such as ErbB2 and membrane ERa, and their affected downstream pathways could account for the differences observed in AVP-induced ERK1/2 activation.
Taylor et al. showed that AVP had mitogenic effects at 10, 100 and 1,000 pM on Mcf7 cells, but an inhibitory effect at 10 nM, that was attributed to a desensitization effect [11] . In apparent contrast to that study, we show here that 10 nM AVP had a mitogenic effect on Mcf7 cells as well as Skbr3 cells. However, our experimental conditions differed from theirs in that their cells were cultured in media containing 2.5% fetal calf serum for three days prior to exposure to AVP, while our cells were cultured in media containing 5% charcoal-stripped serum overnight prior to exposure to AVP. Our conditions were chosen to replicate those of our recent work with SCLC cells, and the increased proliferation in the Mcf7 and Skbr3 cells was comparable to what we observed with H345 and H146 SCLC cells [19] . We did not find a decrease in Mcf7 or Skbr3 cell proliferation when they were cultured in the presence of the V1a receptor antagonist SR49059 alone. It would appear that other growth-promoting pathways, to include V1b receptor-mediated signaling [64] , may compensate for the loss of AVP-mediated V1a signaling under the conditions used for this study, and/or the time-course and exposure to SR49059 was not sufficient to observe cytostatic effects [65] . When SR49059 was included in the culture media in combination with AVP, Mcf7 cell proliferation was partially blocked, but Skbr3 cell proliferation was totally blocked. This may be a result of the persistent ERK1/2 activation observed in Mcf7 cells after AVP exposure, the ability of Mcf7 to produce endogenous AVP, and/or indicate that a V1b receptor mechanism may contribute to Mcf7 cell proliferation. Additionally, it has been postulated that signaling mediated by the V2 receptor may have an anti-proliferative effect on SCLC cells [16, 17] . Taylor et al. demonstrated that the V2-specific agonist dDAVP did not inhibit AVP binding to Mcf7 cells [11] , although later work has shown that these cells do express the V2 receptor [16] . dDAVP can have an anti-metastatic effect on breast cancer cells in mouse tumor models [18, 38] , however those studies indicate that dDAVP did not have a cytotoxic effect on the tumor cells. Additionally, human V1a receptor expressing CHO cells displayed increased thymidine uptake in response to AVP, while human V2 receptor expressing CHO cells displayed a reduction of thymidine uptake [60] . The affinity of AVP for the V1 receptors is approximately 1 nM and it is just over 3 nM for the V2 receptor. Therefore, we expect that at the levels of AVP used in this study we would be activating both V1 and V2 receptors. When the effect of AVP was blocked by SR49059, we did not observe a concomitant inhibition in cell proliferation as a result of V2 pathway stimulation. However we do show that dDAVP at a concentration of 10 nM had a small but statistically significant effect on reducing the proliferation of both Mcf7 and Skbr3 cells, and that this effect was abolished when the cells were incubated with both dDAVP and SR121462. Thus, in reported situations where AVP elicits any anti-proliferative effect, this effect is likely to be mediated through V2 receptor signaling. While this demonstrates that the V2 receptor can mediate an anti-proliferative pathway in these cells, the number of functional V2 receptors on these cells may be low. The effect of AVP on the proliferation of tumor or cultured cells should therefore be affected by receptor expression, functionality, and ligand concentration. Further work will more precisely define AVP-mediated growth mechanisms.
We have recently demonstrated that proAVP protein products can be detected in all human breast cancer tissues examined by IHC analysis, but not in normal breast tissue or fibrocystic tissue that is not associated with malignant breast disease, nor in 65 other various normal human tissues [30] . Together with this study, it appears that most if not all breast cancer cells express the AVP gene. Results here are similar to what is observed with SCLC cells in that proAVP can be targeted at the surface of breast cancer cells by mAbs. Additionally, proAVP protein components can also be secreted and AVP can promote breast cancer cell growth, apparently through V1-type receptors and in an ERK1/2-dependant fashion. Altogether, these results suggest that novel strategies based on proAVP expression could be developed for the successful detection and treatment of breast cancer.
